A Phase 2 interventional study of SGLT2 inhibitor and Placebo in Postoperative Hyperglycemia and Stress Hyperglycemia, sponsored by Zealand University Hospital. Status unknown. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by Zealand University Hospital · Phase 2, Interventional, and Treatment
The aim of the study is to investigate the effect of an SGLT-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes
699 studies on the registry are indexed under Hyperglycemia; 105 are open to participants now.
This study's planned enrollment of 24 is below the median of 46 across 521 interventional studies indexed under Hyperglycemia.
Browse Hyperglycemia studies →Zealand University Hospital is the lead sponsor of 234 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients diagnosed with diabetes mellitus
Drug: SGLT2 inhibitor
Drug: Placebo
10 days of SGLT2 inhibitor after surgery
10 days of placebo after surgery
time in range
percentage of time in range defined as blood glucose between 3.9 and 7.8mmol/l. Blood glucose will be measures continuously while taking the study medication)
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
mean glucose
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
glucose variability
standard deviation divided by the mean and standard deviation
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
time with level 1 hypoglycemia
blood glucose 3.0-3.9mmol/l
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
time with level 2 hypoglycemia
blood glucose less than 3mmol/l
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
time with hyperglycemia
blood glucose more than 10mmol/l
Time frame: from inclusion until 10 days after (or when the patient leaves the hospital)
Quality of recovery-15
Questionnaire assessing the patient's own sense of recovery after surgery
Time frame: every day while taking the study medication and on postoperative day 30
Nanostring
changes in up- and downregulation of genes
Time frame: at inclusion, on day 4 of treatment and at end of treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zealand University Hospital